← Leaderboards
James Dale Berry
Brigham And Women'S Hospital
$37,740,809
Attributed
$131,131,180
Total exposure
8
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $42.6M · FY2017–25$50M$37.5M$25M$12.5M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$129,531,180 · 7
FDA$1,600,000 · 1
By mechanism
U01$62,509,694 · 3
OT2$49,098,369 · 1
UF1$18,136,504 · 1
R21$1,047,373 · 2
U24$339,240 · 1
Top collaborators
- Suma Babu11 shared
- Sabrina Paganoni11 shared
- Oleg Butovsky4 shared
- Jinsy Andrews3 shared
- Jeremy M Shefner3 shared
- Tsuneya Ikezu2 shared
- Philip C Wong1 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Reza Abdi$32,829,278
- Howard L Weiner$38,267,107
- Francisco J. Quintana$15,804,456
- Oleg Butovsky$13,581,013
- Sushrut S. Waikar$14,689,878
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsAmyotrophic Lateral SclerosisParticipantSiteEnrollmentBiologicalPersonsDisease ProgressionDesignCohortCellsMouse ModelSamplingBiological MarkersSerumEnsureDoseGeneral HospitalsCollaborationsPhenotypeResearch PersonnelSafetyFda ApprovedVital Capacity
Grant awards (17)
Access for All in ALS (ALL ALS) East Clinical Coordinating Center$14,357,590
OT2 · FY2025 · NS · contact PI
An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine$7,928,222
U01 · FY2025 · NS
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis$6,151,947
U01 · FY2025 · NS · contact PI
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis$3,993,521
U01 · FY2025 · NS · contact PI
Access for All in ALS (ALL ALS) East Clinical Coordinating Center$15,032,251
OT2 · FY2024 · NS · contact PI
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis$11,665,635
U01 · FY2024 · NS · contact PI
An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine$9,831,153
U01 · FY2024 · NS
Access for All in ALS (ALL ALS) East Clinical Coordinating Center$19,708,528
OT2 · FY2023 · NS · contact PI
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis$11,203,040
U01 · FY2023 · NS · contact PI
An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine$10,136,176
U01 · FY2023 · NS
A diagnostic biomarker for amyotrophic lateral sclerosis$1,600,000
U01 · FY2023 · FD
An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis$18,136,504
UF1 · FY2022 · NS
Harvard Partners Neurology NEXT Clinical Trial Site$339,240
U24 · FY2022 · NS · contact PI
Identification of exosome signature in serum from ALS patients$242,406
R21 · FY2019 · NS
Identification of exosome signature in serum from ALS patients$300,740
R21 · FY2018 · NS
Identification of MicroRNA and Proteomics in immune cells and plasma in ALS$220,238
R21 · FY2018 · NS
Identification of MicroRNA and Proteomics in immune cells and plasma in ALS$283,989
R21 · FY2017 · NS